Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Nervous system disorders – page 15

  • 1 397 clinical trials
  • 586 recruiting
  • 459 conditions
  • 29 countries

Conditions in this area

459 conditions with trials, the busiest first

Dementia Alzheimer's type87Multiple sclerosis59Parkinson's disease56Ischaemic stroke52Migraine48Myasthenia gravis44Glioblastoma41Amyotrophic lateral sclerosis31Duchenne muscular dystrophy28Neuroblastoma26Relapsing multiple sclerosis21Glioma20Relapsing-remitting multiple sclerosis20Narcolepsy19Partial seizures19Cognitive disorder18Epilepsy18Giant cell arteritis18Anaesthesia17Chronic inflammatory demyelinating polyradiculoneuropathy17Spinal muscular atrophy17Subarachnoid haemorrhage16Autism spectrum disorder15Insomnia15+435

Clinical trials in Nervous system disorders

1 397 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 397 clinical trials

Parkinson's disease

Recruiting

Study of safinamide compared to placebo for pain relief in patients with Parkinson's disease who experience motor fluctuations

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Safinamide
  • Sponsor:Azienda Ospedaliera Universitaria Integrata Verona

Neuroblastoma+3

Recruiting

Long-term safety study of GD2IL18CART treatment in patients with neuroblastoma, osteosarcoma, Ewing sarcoma, or advanced breast cancer

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:GD2IL18CART
  • Sponsor:Universitaet Muenster

Ischaemic stroke

Recruiting

Study of Cerebrolysin to improve arm function in patients recovering from ischemic stroke

Registered drug
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Foundation For The Study Of Nanoneuroscience And Neuroregeneration

Atrial fibrillation+1

Recruiting

Study of drug combination therapy for prevention of recurrent stroke in patients with acute ischemic stroke and atrial fibrillation

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Flecainide Acetate
  • Sponsor:University Medical Center Hamburg-Eppendorf

Anaesthesia

Recruiting

Evaluating intravenous lidocaine with intrathecal morphine for pain control in patients undergoing major abdominal surgery through laparotomy

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:GCS Ramsay Sante Enseignement Et Recherche

Parkinson's disease

Recruiting

Study of intestinal gel containing levodopa, carbidopa and entacapone to treat motor and behavioral symptoms in patients with Parkinson's disease

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Entacapone
  • Sponsor:Universitaetsklinikum Tuebingen AöR

Myotonic dystrophy

Recruiting

Study of intravenous AOC 1001 to evaluate long-term safety and effectiveness in patients with myotonic dystrophy type 1

InvestigationalNo placebo
Countries:DenmarkDenmark
  • Participants:0–17 years · 18–64 years
  • Substances:Humanised Igg1 Monoclonal Antibody Against Tfr1 Conjugated To Double Stranded Sirna Oligonucleotide Against Dmpk Via A Non-Cleavable Linker
  • Sponsor:Avidity Biosciences Inc.

Multiple sclerosis

Recruiting

Study of BMS-986368 to treat muscle stiffness in people with Multiple Sclerosis

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:CC-97489
  • Sponsor:Celgene Corp.

Dementia Alzheimer's type

Recruiting

Study of Remternetug for Prevention of Disease Progression in People at Risk for or With Early Onset Inherited Alzheimer's Disease

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:LY3372993
  • Sponsor:Washington University School Of Medicine

Dementia Alzheimer's type

Recruiting

Study of VHB937 to evaluate its effects on cognition and function in people with early Alzheimer's Disease over 72 weeks

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:VHB937
  • Sponsor:Novartis Pharma AG

Parkinson's disease

Recruiting

Study of Atomoxetine to Reduce Freezing of Gait in Patients with Parkinson's Disease During OFF-State

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Atomoxetine
  • Sponsor:Stichting Radboud universitair medisch centrum

Neuroblastoma

Recruiting

Study of Temozolomide, Topotecan, Bevacizumab, Irinotecan and Dinutuximab Beta in Patients with High-Risk Relapsed Neuroblastoma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years
  • Substances:Bevacizumab
  • Sponsor:The University Of Birmingham

Substances studied in this area

The therapies tested most often in Nervous system disorders trials.

Sodium Chloride71 clinical trialsTemozolomide38 clinical trialsOcrelizumab33 clinical trialsRituximab27 clinical trialsCyclophosphamide24 clinical trialsParacetamol24 clinical trialsMethylprednisolone15 clinical trialsPrednisolone15 clinical trialsCarboplatin14 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.